|
|
| FINESSE and CARESS Trials Answer Important Clinical Questions |
Dr. C. Michael Gibson reports the latest on the relationship between lytics and PCI from
the European Society of Cardiology (ESC) 2007. The FINESSE trial suggests that the pre-PCI
administration of Abcximab and Retaplase does not improve PCI outcomes compared to just
simply performing a primary PCI and administering Abcximab in the cath lab. CARESS on the
other hand implies that if you do receive Abcximab, it's better to go on for an urgent PCI
rather than pursue a watchful waiting strategy at the referring hospital. Gibson
concludes that while FINESSE suggests that lytics don't improve PCI outcomes, CARESS
implies that PCI does improve lytic outcomes.
[ Download video ] |
|
No comments have been submitted
|